Many addicts, after long-term sobriety, even though continuing their 12-step work, may experience relapse.
But even if this operation is performed, some patients still experience relapse of the disease.
People discontinuing treatment due to side effects or for other reasons were assumed not to experience relapse in the remaining time after the first line antipsychotic discontinuation occurred.
Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months.
Approximately 15%20%% of patients diagnosed with pancreatic cancer are eligible for surgical resection, and 85% of these patients eventually experience relapse and ultimately cancer-related death (Siegel et al., 2012).
Although many women with recurrent vulvovaginal candidiasis initially benefit from prophylactic intermittent treatment with antimycotics, most of them experience relapse after cessation of therapy, and often they return to the pretreatment recurrence rate.
Unfortunately, most patients still experience relapse, and a multitude of novel agents are currently being tested in this setting, including proteasome inhibitors with bortezomib (the first of its class and first Food and Drug Administration approved drug in MCL), mammalian target of rapamycin inhibitors, Bcl-2 inhibitors, and antiangiogenesis agents, among others.
Studies have suggested that between 40 and upwards of 85percentt of individuals struggling with drug addiction will experience relapse, many within a year of treatment.
Even with these novel drugs, the majority of MM patients eventually experience relapse, their disease becomes chemoresistant, and they die of the disease [6], [7].
Although antipsychotic therapy is a mainstay in the maintenance treatment of schizophrenia, patients still often experience relapse and various adverse events caused by antipsychotic treatment [7].
Unfortunately, the majority of patients who respond to primary chemotherapy later experience relapse.
